20MO Time to deterioration in quality of life in patients (pts) with advanced endometrial cancer (aEC) treated with lenvatinib plus pembrolizumab (L+P) or treatment of physician’s choice (TPC)Domenica Lorusso, V. Makker, Allison Martin Nguyen et al.|Annals of Oncology|2022Cited by 1